Aerie Pharmaceuticals

Aerie Pharmaceuticals Inc (NASDAQ: AERI), a clinical-stage pharmaceutical company that focuses on the treatment of glaucoma and other diseases of the eye, announced on Monday that it has successfully began dosing the first patients enrolled in Mercury 2, the company's second Phase 3 registration...

Aerie Pharmaceuticals Inc (NASDAQ: AERI) has created a lot of buzz this morning as shares jumped 56 percent in pre-market trading following news that the FDA has allowed the company to modify the primary endpoint of its second Phase 3 trial of Rhopressa; an eye drop that alleviates intraocular...